title: Diabetes mellitus in Tassin, France: remarkable transformation in incidence and outcome of ESRD in diabetes.
abstract: The incidence and prevalence of diabetes mellitus (DM) in the dialysis population in Europe, and more especially in France, have been lagging behind the impressive United States and Japanese rates. For a decade, things have been changing, and the incidence of DM in hemodialysis (HD) reached almost 40 in Tassin, France in 1999. The prevalence has followed the same trend but increased more slowly. The increase in incidence and prevalence is almost totally accounted for by type 2 DM explosive outbreak and development. The morbidity on dialysis (hypotensive episodes, hospitalization number, and duration) was significantly worse in diabetic patients (without difference between type 1 and 2) than in nondiabetic patients. The mortality rate was higher in diabetic patients than in nondiabetic patients (mean half-life 3 and 13 years, respectively), even after adjustment for age and comorbidity. The mortality rate was higher in type 2 than in type 1 (mean half-life 2.7 and 5.2 years, respectively), a difference which disappears when adjusting for age and comorbidity. Specific causes of death were different in diabetic and nondiabetic HD patients; in diabetics there was a six-fold higher cardiovascular (CV) and three-fold higher infectious mortality, but there was the same mortality from cancer. A strong difference was observed between type 1 and type 2 DM: in type 1 there was no increased infectious mortality and a moderately increased CV mortality compared with nondiabetic patients. Type 2 diabetic patients had a four-fold increased infectious and an eight-fold increased CV mortality. Altogether, the eruption of DM in our unit over the last decade has drastically increased the crude mortality, but the standardized mortality ratio using the USRDS mortality table remained unchanged, about 45 of expected mortality.
authors.affiliation: Centre de rein artificiel, Tassin, France. bcharra@aol.com
authors.forename: B
authors.initials: B
authors.lastname: Charra
authors.forename: C
authors.initials: C
authors.lastname: VoVan
authors.forename: D
authors.initials: D
authors.lastname: Marcelli
authors.forename: M
authors.initials: M
authors.lastname: Ruffet
authors.forename: G
authors.initials: G
authors.lastname: Jean
authors.forename: J M
authors.initials: JM
authors.lastname: Hurot
authors.forename: J C
authors.initials: JC
authors.lastname: Terrat
authors.forename: T
authors.initials: T
authors.lastname: Vanel
authors.forename: C
authors.initials: C
authors.lastname: Chazot
mesh_terms: D000328:Adult; D000368:Aged; D002423:Cause of Death; D003922:Diabetes Mellitus, Type 1 / Q000401:mortality*; D003924:Diabetes Mellitus, Type 2 / Q000401:mortality*; D003928:Diabetic Nephropathies / Q000401:mortality* / Q000628:therapy; D005260:Female; D005602:France / Q000453:epidemiology; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D015995:Prevalence; D017582:Renal Replacement Therapy / Q000706:statistics & numerical data; D016019:Survival Analysis